New combo therapy targets tough breast cancers in early trial

NCT ID NCT05810870

Ongoing Disease control Sponsor: MedSIR Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug (MEN1611) combined with chemotherapy (eribulin) for people with advanced breast cancer that has specific genetic changes (PIK3CA/PTEN). The goal is to see if the combination can shrink tumors or stop them from growing. About 14 participants will receive the treatment, and researchers will monitor safety and effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm hormone receptor-positive breast cancer metaplastic breast carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER BREAST CANCER METASTATIC BREAST CANCER

Contacts and locations

Locations

CHUVI - Complejo Hospitalario Universitario de Vigo

Vigo, Pontevedra, 36312, Spain
Centro Oncológico de Galicia

A Coruña, Galicia, 15009, Spain
Hospital Beata María Ana

Madrid, Spain
Hospital Clínic i Provincial de Barcelona

Barcelona, 08036, Spain
Hospital Clínico San Carlos

Madrid, 28040, Spain
Hospital Universitari Vall D'Hebron

Barcelona, Spain
Hospital Universitario Clínico San Cecilio de Granada

Granada, Andalusia, 18016, Spain
Hospital Universitario Marqués de Valdecilla

Santander, Cantabria, 39008, Spain
Hospital Universitario Virgen del Rocio

Seville, Andalusia, 41013, Spain
Hospital Universitario de Torrejón

Torrejón de Ardoz, Madrid, 28850, Spain
Institut Català d' Oncologia L'Hospitalet (ICO)

Barcelona, 08907, Spain
Instituto Valenciano de Oncología (IVO)

Valencia, 46009, Spain
Onkologikoa

Donostia / San Sebastian, Basque Country, 20014, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.